Samsung Biologics said on the 22nd it signed three contract manufacturing organization (CMO) deals with a Europe-based pharmaceutical company totaling 1.223 trillion won. This marks the first order in the 1 trillion won range achieved by Samsung Biologics since launching as a pure contract development and manufacturing organization (CDMO) following a spin-off.
All contracts run through the end of 2030. The client and product names were not disclosed for business confidentiality reasons, and no separate upfront payment was included. The counterparty is scheduled to be disclosed at the end of the contract.
The market views these orders as contract manufacturing volumes to be carried over from the antibody drug plant in Rockville, Maryland, that Samsung Biologics acquired. Samsung Biologics said the same day it secured its first production base in the United States by signing a deal with GSK to acquire Human Genome Sciences' biopharmaceutical manufacturing facility located in the area.
The buyer is the U.S. subsidiary Samsung Biologics America, and the purchase price is $280 million (about 414.7 billion won). The asset acquisition process is expected to be completed within the first quarter of next year.
Samsung Biologics' cumulative orders this year total 6.819 trillion won, up 26.1% from last year's annual orders (5.4035 trillion won), setting a record high. The company said that with the recent 1,000-liter capacity addition at its Songdo, Incheon, plant and the securing of the Rockville, U.S., plant (60,000 liters), it now has one of the world's largest biopharmaceutical manufacturing capacities at 845,000 liters.